132 related articles for article (PubMed ID: 21429402)
1. [In vitro synergistic effect of bortezomib and pirarubicin on proliferation and apoptosis of T cell lymphoma cell line Hut-78 cells].
Qian ZZ; Wang HQ; Fu K; Ma YL; Hao XS
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):47-51. PubMed ID: 21429402
[TBL] [Abstract][Full Text] [Related]
2. [Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin].
Chen JF; Jin J
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):890-3. PubMed ID: 20193325
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.
Du BY; Song W; Bai L; Shen Y; Miao SY; Wang LF
Chemotherapy; 2012; 58(1):44-51. PubMed ID: 22327308
[TBL] [Abstract][Full Text] [Related]
4. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
[TBL] [Abstract][Full Text] [Related]
7. [Synergistic inhibitory effect of all-trans retinoic acid and 1,25-dihydroxy vitamin D3 on growth of human hepatoma cell line HepG2].
Lu HQ; Zheng J
Ai Zheng; 2006 Dec; 25(12):1470-6. PubMed ID: 17166369
[TBL] [Abstract][Full Text] [Related]
8. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Huang JJ; Li ZM; Huang Y; Huang Y; Tian Y; He XX; Xiao J; Lin TY
Invest New Drugs; 2012 Feb; 30(1):223-35. PubMed ID: 20960030
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
13. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
Sato A; Asano T; Ito K; Asano T
Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Ri M; Iida S; Ishida T; Ito A; Yano H; Inagaki A; Ding J; Kusumoto S; Komatsu H; Utsunomiya A; Ueda R
Cancer Sci; 2009 Feb; 100(2):341-8. PubMed ID: 19068089
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro.
Songgang L; Jiyu L; Gongwei ; Yingbin L; Yiyu Q; Zhiwei Q
Hepatogastroenterology; 2009; 56(94-95):1253-60. PubMed ID: 19950772
[TBL] [Abstract][Full Text] [Related]
16. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Wang M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q
Leukemia; 2008 Jan; 22(1):179-85. PubMed ID: 17898787
[TBL] [Abstract][Full Text] [Related]
18. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
[TBL] [Abstract][Full Text] [Related]
19. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
Verheul HM; Qian DZ; Carducci MA; Pili R
Cancer Chemother Pharmacol; 2007 Aug; 60(3):329-39. PubMed ID: 17256134
[TBL] [Abstract][Full Text] [Related]
20. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]